Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Printable Handouts
Navigable Slide Index
- Introduction
- Antibody structure
- Antibodies - nature's pro-drugs
- Key properties of antibodies relevant to therapy
- Antibodies are different from conventional drugs
- Treatment of sarcoma by serotherapy
- Conclusions from Hericourt and Richet
- Paul Ehrlich 1854-1915
- Modes of antibody therapy
- Problems with polyclonal antisera
- Making monoclonal antibodies
- Pros and cons of monoclonal antibodies
- Antibodies for cell depletion
- Genetic engineering of antibodies
- Chimeric antibodies
- Making chimeric antibodies
- Effector functions of anti-NP antibodies
- Humanised antibodies
- Making humanised antibodies by phage display
- Making phage antibodies
- Infection, replication and enrichment
- Pros and cons of phage antibodies
- Antibodies from transgenic mice
- Antibody nomenclature: source
- Immunogenicity of therapeutic Mabs
- Immunogenicity
- Factors influencing the antiglobulin response
- Some observations
- Increasing antibody affinity
- Antibodies for tumour therapy
- CD20 antigen
- CD20 and B cell development
- Phase III trial of rituximab in follicular lymphoma
- CD20 epitopes
- Type I and II antibodies
- Anti-CD20 antibodies
- Antibodies for immunomodulation
- Tumour necrosis factor (TNF)
- Physiology of TNF
- Phase III trial of infliximab in rheumatoid arthritis
- Anti-TNF antibodies
- CD52 antigen
- CD52 antigen structure
- Treatment with rat CD52 antibodies
- Treatment of lymphoma with alemtuzumab
- Alemtuzumab effectively suppresses relapses
- Change in disability after alemtuzumab treatment
- Phase III trial of alemtuzumab in multiple sclerosis
- Approval of antibodies and fusion proteins
- Therapeutic antibodies & fusion proteins
- Thank you
Topics Covered
- Why antibodies are so useful as drugs
- Antibody therapy
- The development of monoclonal antibodies
- Genetic engineering
- The problem of unwanted immunogenicity
- The importance of affinity
- Examples of antibodies for treatment of cancer
- Examples of antibodies for treatment of immunological diseases
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Hale, G. (2020, October 29). Therapeutic antibodies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 21, 2021, from https://hstalks.com/bs/4433/.Publication History
Financial Disclosures
- Dr. Geoffrey Hale has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Therapeutic antibodies
Published on October 29, 2020
49 min